Postmarket User Fees Floated At House Subcommittee Hearing
This article was originally published in The Gray Sheet
Executive Summary
The chairman of the House subcommittee overseeing reauthorization of medical device user fees is signaling that he might push to have a portion of industry-provided funds specifically allocated for FDA postmarket activities